INVEX Therapeutics Ltd Market Cap ($4.52 Million)
Market Cap & Net Worth: INVEX Therapeutics Ltd (IXC)
INVEX Therapeutics Ltd market cap. INVEX Therapeutics Ltd (AU:IXC) has a market capitalization of $4.52 Million (AU$6.39 Million) as of November 12, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28691 globally and #1529 in its home market, demonstrating a -29.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INVEX Therapeutics Ltd's stock price AU$0.09 by its total outstanding shares 75153848 (75.15 Million). Also see how efficiently does INVEX Therapeutics Ltd generate cash for how efficiently the company converts equity into cash flow.
INVEX Therapeutics Ltd Market Cap History (2019–2026)
INVEX Therapeutics Ltd market cap history from 2019 to 2026. Data shows change from $45.73 Million to $4.52 Million (-29.16% CAGR). Check today's stock price for INVEX Therapeutics Ltd for real-time trading data and today's change.
INVEX Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INVEX Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore INVEX Therapeutics Ltd (IXC) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
27.86x
INVEX Therapeutics Ltd's market cap is 27.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $45.73 Million | $130.00 | -$232.00K | 351780.59x | N/A |
| 2020 | $38.02 Million | $165.70K | -$3.36 Million | 229.46x | N/A |
| 2021 | $37.49 Million | $158.79K | -$2.28 Million | 236.09x | N/A |
| 2022 | $28.98 Million | $182.25K | -$3.95 Million | 159.02x | N/A |
| 2023 | $4.31 Million | $459.08K | -$7.75 Million | 9.38x | N/A |
| 2024 | $3.51 Million | $1.21 Million | -$1.64 Million | 2.90x | N/A |
| 2025 | $6.38 Million | $229.08K | -$476.87K | 27.86x | N/A |
Competitor Companies of IXC by Market Capitalization
Companies near INVEX Therapeutics Ltd in the global market cap rankings as of November 12, 2026. Also see balance sheet size of INVEX Therapeutics Ltd for a full breakdown of the balance sheet.
Key companies related to INVEX Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #370 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $69.23 Billion USD ( AU$97.85 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.03 |
| #370 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $959.41 |
| #414 | CSL Ltd | AU:CSL | $69.23 Billion | AU$201.68 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $248.69 |
Market Capitalization of INVEX Therapeutics Ltd (2019–2026)
Market capitalization of INVEX Therapeutics Ltd from 2019 to today. Between 2019 and today, INVEX Therapeutics Ltd's market cap moved from $45.73 Million to $ 4.52 Million, with a yearly change of -29.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$4.52 Million | -29.17% |
| 2025 | AU$6.38 Million | +81.82% |
| 2024 | AU$3.51 Million | -18.52% |
| 2023 | AU$4.31 Million | -85.14% |
| 2022 | AU$28.98 Million | -22.70% |
| 2021 | AU$37.49 Million | -1.40% |
| 2020 | AU$38.02 Million | -16.86% |
| 2019 | AU$45.73 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 12th, 2026 the market cap of INVEX Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.52 Million USD |
| MoneyControl | $4.52 Million USD |
| MarketWatch | $4.52 Million USD |
| marketcap.company | $4.52 Million USD |
| Reuters | $4.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has comple… Read more